Takeda Pharmaceutical Company Limited
TKPHF
$30.58
$0.391.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.79B | 29.85B | 29.62B | 29.99B | 30.08B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.79B | 29.85B | 29.62B | 29.99B | 30.08B |
| Cost of Revenue | 10.68B | 10.29B | 10.42B | 10.50B | 10.32B |
| Gross Profit | 19.11B | 19.56B | 19.20B | 19.49B | 19.76B |
| SG&A Expenses | 7.15B | 7.27B | 7.21B | 7.29B | 7.25B |
| Depreciation & Amortization | 3.32B | 3.57B | 3.56B | 3.61B | 3.60B |
| Other Operating Expenses | 184.36M | 27.82M | 511.19M | 103.75M | 404.49M |
| Total Operating Expenses | 25.74B | 25.80B | 26.33B | 26.21B | 26.37B |
| Operating Income | 4.05B | 4.05B | 3.29B | 3.78B | 3.71B |
| Income Before Tax | -745.71M | 1.40B | 703.04M | 1.32B | 1.15B |
| Income Tax Expenses | 106.36M | 620.97M | 442.33M | 355.19M | 437.74M |
| Earnings from Continuing Operations | -852.07 | 777.52 | 260.71 | 959.94 | 710.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.74M | -1.72M | -1.41M | -1.34M | -1.41M |
| Net Income | -853.81M | 775.80M | 259.30M | 958.61M | 709.46M |
| EBIT | 4.05B | 4.05B | 3.29B | 3.78B | 3.71B |
| EBITDA | 9.84B | 10.26B | 10.38B | 10.91B | 10.81B |
| EPS Basic | -0.53 | 0.50 | 0.17 | 0.61 | 0.45 |
| Normalized Basic EPS | 1.24 | 1.36 | 0.94 | 1.12 | 1.11 |
| EPS Diluted | -0.55 | 0.48 | 0.16 | 0.60 | 0.44 |
| Normalized Diluted EPS | 1.23 | 1.34 | 0.94 | 1.10 | 1.09 |
| Average Basic Shares Outstanding | 6.30B | 6.30B | 6.31B | 6.31B | 6.32B |
| Average Diluted Shares Outstanding | 6.35B | 6.35B | 6.33B | 6.36B | 6.37B |
| Dividend Per Share | 1.30 | 1.32 | 1.32 | 1.30 | 1.30 |
| Payout Ratio | -244.50% | 270.24% | 803.40% | 217.56% | 277.06% |